OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO(TM) Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma
Stock Information for OncoSec Medical Incorporated
Loading
Please wait while we load your information from QuoteMedia.